Information  X 
Enter a valid email address

Angel Biotechnology (ABH)

  Print      Mail a friend

Tuesday 16 November, 2010

Angel Biotechnology

First Patient Treated with Re

RNS Number : 2557W
Angel Biotechnology Holdings Plc
16 November 2010
 



 

 

For immediate release

16 November 2010

 

ANGEL BIOTECHNOLOGY HOLDINGS PLC

("Angel" or "the Company")

 

Angel manufactures stem cells used in

in landmark clinical trial for stroke patients

 

Further to the announcement issued by ReNeuron Group plc on 16 November 2010 (RNS number 2284W), Angel Biotechnology Holdings plc, (AIM: ABH)the biopharmaceutical contract manufacturer, is pleased to announce that the stem cells being used in the Phase I clinical trial for disabled stroke patients are being produced at Angel's Edinburgh facility.

 

The Company has been ReNeuron's manufacturing partner for over three years and is producing the GMP grade ReN001 stem cell therapy for stroke under a previously announced contract. The ground breaking Phase I clinical trial is being conducted at the Southern General Hospital in Glasgow. 

 

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: "Angel is very pleased to be manufacturing the ReN001 stem cell product for the clinical trial.   This is a world first, an important landmark in the development of cellular therapies and a tribute to the dedication of the ReNeuron and Angel team. 

 

"The critical nature of the work has drawn upon Angel's technical and regulatory expertise to provide ReNeuron with clinical material of the highest quality to conduct its trial.  This is Angel's core competence and commencement of this clinical trial further strengthens Angel's track record of working with advanced therapy medicinal products, supporting our client's clinical development from Phase I through to commercial launch."

 

 

For further information, please call:

Angel Biotechnology Holdings plc

Tel: +44 (0) 131 445 6077

Gordon Sherriff - COO

Tel: +44 (0) 7951 057016

Grant Thornton Corporate Finance

Tel: +44 (0) 20 7383 5100 

Philip Secrett, Colin Aaronson


Matrix Corporate Capital LLP

Tel +44 (0) 20 3206 7000

Steve Cox/Stephen Waterman


The Communications Portfolio Ltd

Tel +44 (0) 20 7536 2028

Ariane Comstive, Media enquiries


About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing for advanced biologics, supporting biotechnology and pharmaceutical companies worldwide.  Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.  Angel specializes in the provision of advanced biologics including  autologous and allogeneic cell therapy products including stem cells and cellular vaccines, specific purified natural and recombinant proteins and bacteriophage.  Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag.

Angel was admitted to trading on AIM in November 2005.

More information at www.angelbio.com.

About ReNeuron Group plc

 

ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.  

 

ReNeuron has used its proprietary, patented cell expansion technology to generate genetically stable neural stem cell lines.  This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch.  Cell growth can therefore be completely arrested prior to in vivo implantation.  ReNeuron's clinically-tested cell encapsulation technology provides a method of protecting cells when transplanted, as well as reducing or eliminating the host immune response that might otherwise occur post-transplantation.

 

ReNeuron has filed for approval to commence initial clinical studies with its lead ReN001 stem cell therapy for chronic stroke disability.  There are an estimated 50 millionstroke survivors worldwide, approximately one half of which are left with permanent disabilities.  The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US.  In addition to its stroke programme, ReNeuron is developing stem cell therapies for Parkinson's disease, Huntington's disease, Type 1 diabetes and diseases of the retina.

 

ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas - its ReNcell®range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry.  ReNeuron's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by Millipore Corporation.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKKADKKBDDNDD

a d v e r t i s e m e n t